51 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Inhibition of O-GlcNAcase (OGA): A Potential Therapeutic Target to Treat Alzheimer's Disease.
Therachem Research Medilab (India)
Elevation of cellular O-GlcNAcylation level by a potent and selective O-GlcNAcase inhibitor based on tetrahydroimidazopyridine scaffold.
Nankai University
N-Acetylhexosaminidase inhibitory properties of C-1 homologated GlcNAc- and GalNAc-thiazolines.
The State University of New Jersey
A potent mechanism-inspired O-GlcNAcase inhibitor that blocks phosphorylation of tau in vivo.
Simon Fraser University
Structure-based discovery and development of novel O-GlcNAcase inhibitors for the treatment of Alzheimer's disease.
Chonnam National University
Nanomolar inhibition of human OGA by 2-acetamido-2-deoxy-d-glucono-1,5-lactone semicarbazone derivatives.
University of Debrecen
Benzo[d]thiazol-5-yl Compounds as O-GlcNAcase Inhibitors for Treating Alzheimer's Disease.
Smith, Gambrell & Russell
Diazaspirononane Nonsaccharide Inhibitors of O-GlcNAcase (OGA) for the Treatment of Neurodegenerative Disorders.
Janssen-Cilag
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
Merck
Diazaspirononane Inhibitors of O-GlcNAc Hydrolase for the Treatment of Central Nervous System Diseases.
Drexel University
Modification of the Thioglycosyl-Naphthalimides as Potent and Selective Human O-GlcNAcase Inhibitors.
China Agricultural University
Tau protein aggregation in Alzheimer's disease: An attractive target for the development of novel therapeutic agents.
University of Caen Normandie
Interrogating the Roles of Post-Translational Modifications of Non-Histone Proteins.
Temple University
Selective inhibition of β-N-acetylhexosaminidases by thioglycosyl-naphthalimide hybrid molecules.
Dalian University of Technology
Isoxazolo-quinazolines as modulators of protein kinase activity
Nerviano Medical Sciences
2-aminoquinoline-based compounds for potent and selective neuronal nitric oxide synthase inhibition
Northwestern University
Synthesis and characterization of new piperazine-type inhibitors for mitochondrial NADH-ubiquinone oxidoreductase (complex I).
Kyoto University
Pharmacological properties of (2R)-N-[1-(6-aminopyridin-2-ylmethyl)piperidin-4-yl]-2-[(1R)-3,3-difluorocyclopentyl]-2-hydroxy-2-phenylacetamide: a novel mucarinic antagonist with M(2)-sparing antagonistic activity.
Banyu Pharmaceutical
Characterization of the binding site for a novel class of noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor antagonists.
Pfizer
Muscarinic receptor binding sites of the M4 subtype in porcine lung parenchyma.
Case Western Reserve University
The cloning and chromosomal mapping of two novel human opioid-somatostatin-like receptor genes, GPR7 and GPR8, expressed in discrete areas of the brain.
Addiction Research Foundation
Comparison of the pharmacological characteristics of [3H]raclopride and [3H]SCH 23390 binding to dopamine receptors in vivo in mouse brain.
Novo Industri
8-Cyclopentyl-1,3-dipropylxanthine (DPCPX)--a selective high affinity antagonist radioligand for A1 adenosine receptors.
UniversitÄT Heidelberg
Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.
Abbott Laboratories